	PV-infected cells	PV-infected cells treated with GnHCl
Total number of LDs	189	167
Number of LDs within a distance of 30nm from the RCs	117	13
Percentage of LD within a distance of 30nm from the RCs	62%	8%

Table S1. Quantification of LD-RC membrane contact sites in TEM images of PV-infected cells at 6hpi, related to Figures 2, 7E and S6. The number of LDs which are within a distance of 30nm from at least one RC was scored in thin TEM sections of randomly chosen PV-infected cells and PV-infected cells treated with GnHCl at 4hpi (14 cells for each condition in 2 independent experiments).

Treatment	HeLa cell viability (% of DMSO treated cells, mean±SD)	Huh7 cell viability (% of DMSO treated cells, mean±SD)	Caco2 cell viability (% of DMSO treated cells, mean±SD)	RD cell viability (% of DMSO treated cells, mean±SD)
CAY10499 (20µM)				92±2
CAY10499 (100µM)	95±4	87±5		
Atglistatin (100µM)	98±1	87±3	94±2	
PF-04620110 (20µM)	98±3	102±4		

Table S2. A summary of cell viability under various pharmacological treatments used in this study, related to Figures 5, 6 and S4. Cell viability was measured by the CellTiter-Glo luminiscent cell viability assay (Promega). Mean ± standard deviation values normalized to control DMSO-treated cells from 2 independent experiments are shown.

Construct		Oligos
rat HSL-Myc	Forward	5'AGGAAGCTTGACATGGATTTACGCACAATGACACAG 3'
	Reverse	5'AAGCTCGAGTTAAACCAGATCCTCTTCAGAGATGAGTTTCTGCTCGGTCAGCGGTGCAGCAGG 3'
Strep-2B(1-57)	Forward	5' AAAGAATTCACCATGGGCATCACCAATTAC 3'
	Reverse	5' AAACTCGAGGTTCCTAGTTATAATAACTAGTGAGGATATGATCTTG 3'
Strep-2B(56-97)	Forward	5' AAAGAATTCAGGATGAGGAACTATGAAGACACCACAACAG 3'
	Reverse	5' AGGCTCGAGTTGCTTGATGACATAAGGTATCTCC 3'
Strep-2C(1-38)	Forward	5' AAAGAATTCAGGATGGGTGACAGTTGGTTGAAGAAG 3'
	Reverse	5' AAAGTCGACGATAATTTTCTCCTTGAGCCAATC 3'
Strep-2C(1-67)	Forward	5' AAAGAATTCAGGATGGGTGACAGTTGGTTGAAGAAG 3'
	Reverse	5' AAACTCGAGGCATGATTGGTGTATAGTTGAGATTTG 3'
Strep-2C(1-91)	Forward	5' AAAGAATTCAGGATGGGTGACAGTTGGTTGAAGAAG 3'
	Reverse	5' AGTGTCGACGGCAAACCTCTTAGACTGGATG 3'
Strep-2C(40-329)	Forward	5'AAAGAATTCAGGATGCAAGCTAGAGATAAGTTGGAATTTG 3'

	Reverse	5' AGACTCGAGTTGAAACAAAGCCTCCATACAATTG 3'
Strep-2CΔ(17-38)	Forward	5' CATGCAACGCAGCTAAGGGACAAGCTAGAGATA AGTTGGAATTTG 3'
	Reverse	5' CAAATTCCAACTTATCTCTAGCTTGTCCCTTAGCTG CGTTGCATG 3'

Table S3. A list of oligonucleotide primers used in PCR for the generation of constructs described in this study, related to STAR Methods.